A BRICS+ parallel-health framework signed by 5+ states by 2028, with pharma supply-chain impact?

By mid-2028, at least five BRICS+ countries have signed a formal health cooperation agreement that establishes shared standards for drug approval, coordinates bulk procurement of essential medicines, and creates a joint vaccine development facility in India or China. Generic manufacturers in these countries gain fast-track access to each other's markets without requiring separate FDA-equivalent approvals. European and North American pharma companies face new pressure: either accept the BRICS+ approval pathway as sufficient for their products or lose access to markets representing over 40% of the world's population. Supply chains begin splitting into two zones with different regulatory languages.

BRICS+ health ministers continue meeting annually and issue joint communiqués, but no binding treaty emerges by mid-2028. Countries maintain their individual drug approval systems, and pharmaceutical supply chains remain globally integrated under existing WHO and ICH frameworks. Attempts to establish a parallel approval system stall over intellectual property disputes, differing safety standards, and the high cost of building independent regulatory infrastructure. China and India pursue bilateral agreements on specific drug categories, but these don't scale into a broader multi-country framework. Western pharma companies continue operating under one set of international norms.